Harbour Investments’s Karyopharm Therapeutics KPTI Stock Holding History

Harbour Investments’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.78K	Hold	285	–	–	﹤0.01%	3917
2026 Q1	$1.59K	Buy	285 +200	+235%	+$1.52K	﹤0.01%	3978
2025 Q4	$626	Hold	85	–	–	﹤0.01%	3516
2025 Q3	$556	Hold	85	–	–	﹤0.01%	3496
2025 Q2	$366	Hold	85	–	–	﹤0.01%	3418
2025 Q1	$318	Sell	85 -2	-2%	-$17	﹤0.01%	3389
2024 Q4	$879	Hold	87	–	–	﹤0.01%	3195
2024 Q3	$1.08K	Hold	87	–	–	﹤0.01%	3081
2024 Q2	$1.13K	Hold	87	–	–	﹤0.01%	2972
2024 Q1	$1.96K	Hold	87	–	–	﹤0.01%	2784
2023 Q4	$1.13K	Hold	87	–	–	﹤0.01%	2799
2023 Q3	$1.74K	Hold	87	–	–	﹤0.01%	2585
2023 Q2	$2.33K	Buy	87 +34	+64%	+$1.46K	﹤0.01%	2505
2023 Q1	$3.11K	Hold	53	–	–	﹤0.01%	2445
2022 Q4	$2.72K	Hold	53	–	–	﹤0.01%	2439
2022 Q3	$4K	Hold	53	–	–	﹤0.01%	2246
2022 Q2	$4K	Buy	+53	New	+$4.86K	﹤0.01%	2246
2021 Q4	$5K	Sell	53 -134	-72%	-$13.4K	﹤0.01%	2175
2021 Q3	$16K	Buy	187 +20	+12%	+$2.08K	﹤0.01%	2417
2021 Q2	$26K	Sell	167 -173	-51%	-$25.1K	﹤0.01%	2193
2021 Q1	$54K	Buy	+340	New	+$71.6K	﹤0.01%	1657

Other funds holding KPTI

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CCM

Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Harbour Investments's KPTI Position: Q2 2026 in Review

Harbour Investments held its Karyopharm Therapeutics (KPTI) position steady in Q2 2026 at 285 shares worth $2.78K. The position accounts for ﹤0.01% of the portfolio, ranked #3917.

Harbour Investments first reported a position in KPTI in Q1 2021 and has held it in 21 quarters since. The position peaked at $54K in Q1 2021. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

Harbour Investments held 285 shares of Karyopharm Therapeutics worth $2.78K as of Q2 2026.
Harbour Investments left its Karyopharm Therapeutics share count unchanged in Q2 2026.
Karyopharm Therapeutics made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #3917 holding.
Harbour Investments first reported a position in Karyopharm Therapeutics in Q1 2021 and has held it in 21 quarters since.
Harbour Investments's Karyopharm Therapeutics position peaked at $54K in Q1 2021.
97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.